These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 39078788)
1. Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB. Liu D; Jie F; Ding Y; Qu H; Chen D; Huang J J Infect Dev Ctries; 2024 Jul; 18(7):1050-1057. PubMed ID: 39078788 [TBL] [Abstract][Full Text] [Related]
2. Outcome of intravenous and inhaled polymyxin B treatment in patients with multidrug-resistant gram-negative bacterial pneumonia. Ding P; Li H; Nan Y; Liu C; Wang G; Cai H; Yu W Int J Antimicrob Agents; 2024 Oct; 64(4):107293. PubMed ID: 39094752 [TBL] [Abstract][Full Text] [Related]
3. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066 [TBL] [Abstract][Full Text] [Related]
4. Comparative study of polymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB. Wang J; Shah BK; Zhao J; Xiong J; Wang C; Xie S BMC Infect Dis; 2023 May; 23(1):351. PubMed ID: 37231342 [TBL] [Abstract][Full Text] [Related]
5. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy? Ardebili A; Izanloo A; Rastegar M Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511 [TBL] [Abstract][Full Text] [Related]
6. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Petrosillo N; Giannella M; Antonelli M; Antonini M; Barsic B; Belancic L; Inkaya A C; De Pascale G; Grilli E; Tumbarello M; Akova M Antimicrob Agents Chemother; 2014; 58(2):851-8. PubMed ID: 24277037 [TBL] [Abstract][Full Text] [Related]
7. Polymyxin B adjuvants against polymyxin B- and carbapenem-resistant Gram-negative bacteria. Salvaterra Pasquini JP; Queiroz PA; Rodrigues do Amaral PH; da Silva TC; Souza Bonfim Mendonça P; Vandresen F; Carvalho Ceolis JP; de Lima Scodro RB; Caleffi-Ferracioli KR; Cardoso RF; Dias Siqueira VL Future Microbiol; 2024; 19(17):1445-1454. PubMed ID: 39258398 [TBL] [Abstract][Full Text] [Related]
8. Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Vieceli T; Henrique LR; Rech TH; Zavascki AP J Infect Chemother; 2024 Jul; 30(7):621-625. PubMed ID: 38244722 [TBL] [Abstract][Full Text] [Related]
9. Carbapenem-resistant gram-negative bacterial infections and risk factors for acquisition in a Kenyan intensive care unit. Maina JW; Mutua JM; Musyoki AM BMC Infect Dis; 2024 May; 24(1):522. PubMed ID: 38783175 [TBL] [Abstract][Full Text] [Related]
10. Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series. Falagas ME; Siempos II; Rafailidis PI; Korbila IP; Ioannidou E; Michalopoulos A Respir Med; 2009 May; 103(5):707-13. PubMed ID: 19118994 [TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study. Zhang X; Qi S; Duan X; Han B; Zhang S; Liu S; Wang H; Zhang H; Sun T J Transl Med; 2021 Oct; 19(1):431. PubMed ID: 34656132 [TBL] [Abstract][Full Text] [Related]
12. Rational use of intravenous polymyxin B and colistin: A review. Zakuan ZD; Suresh K Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826 [TBL] [Abstract][Full Text] [Related]
13. A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections. Lu Q; Zhu HH; Li GH; Qi TT; Ye LJ; Teng XQ; Qu Q; He GF; Qu J Front Med (Lausanne); 2021; 8():620885. PubMed ID: 33634151 [No Abstract] [Full Text] [Related]
14. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections. Huang J; Tang YQ; Sun JY Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424 [TBL] [Abstract][Full Text] [Related]
15. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria. Doymaz MZ; Karaaslan E Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061 [No Abstract] [Full Text] [Related]
16. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend. Balkhair A; Al-Muharrmi Z; Al'Adawi B; Al Busaidi I; Taher HB; Al-Siyabi T; Al Amin M; Hassan KS Int J Infect Dis; 2019 Aug; 85():10-15. PubMed ID: 31100418 [TBL] [Abstract][Full Text] [Related]
17. Colistin and polymyxin B in critical care. Michalopoulos A; Falagas ME Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952 [TBL] [Abstract][Full Text] [Related]
18. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems. Karakonstantis S; Kritsotakis EI; Gikas A Infection; 2020 Dec; 48(6):835-851. PubMed ID: 32875545 [TBL] [Abstract][Full Text] [Related]
19. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Tumbarello M; De Pascale G; Trecarichi EM; De Martino S; Bello G; Maviglia R; Spanu T; Antonelli M Chest; 2013 Dec; 144(6):1768-1775. PubMed ID: 23989805 [TBL] [Abstract][Full Text] [Related]
20. Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia and tracheobronchitis caused by Pseudomonas aeruginosa or Acinetobacter baumannii. Rigatto MH; Ribeiro VB; Konzen D; Zavascki AP Infection; 2013 Apr; 41(2):321-8. PubMed ID: 23124906 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]